Fig. 3
From: SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia
Prognostic value of SLC22A3 methylation in AML and MDS patients. A, B The impact of SLC22A3 methylation on OS and LFS of CN-AML, and non-APL AML patients, respectively. AML patients were treated by “3 + 7” induction regimens. C, D The impact of SLC22A3 methylation on OS among MDS patients. SLC22A3 methylation was measured using RQ-MSP (C) and MethylTarget assay (D)